BioSpace News Archive

Prolacta Bioscience®, reports that data from a growing body of peer-reviewed clinical studies show a reduced risk of several comorbidities among premature infants who received Prolacta’s 100% human milk-based fortifiers as part of Exclusive Human Milk Diet (Prolacta’s EHMD), compared to premature infants fed cow milk-based fortifiers.

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the release of Illumina DRAGEN™ v4.0, its most accurate and comprehensive secondary analysis platform.

Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of the Mantarray™ platform for human-relevant 3D heart and skeletal engineered muscle tissue (EMT) contractility analysis.

City of Hope, one of the largest cancer research and treatment organizations in the United States, opens its visionary comprehensive cancer center in Orange County, California, creating a national model for delivering breakthrough research and pioneering treatments.

The service has highly supported research related to protein identification, analysis, sequence analysis and characterization of post-translational modifications.

NuGen Medical Devices Inc., a leader in needle-free drug delivery, is pleased to announce that, effective July 27, 2022, its common shares will commence trading on the OTCQB under the symbol NGMDF.

Creative Bioarray also utilizes the latest technology or proprietary protocols to authenticate and develop quality products that drive innovation and standards in science.

Recently, Creative Biogene announced the release of its high quality transfection reagents which can be applie to deliver mRNA in a variety of cells or in vivo.

Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx” or the “Company”), announced today that it will be attending and speaking at the Yale School of Public Health SalivaDirect™ Conference held July 28-29 in Chicago, Il.

A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from a series of pharmacokinetics studies conducted with Humanetics Corporation’s new radioprotective drug, BIO 300.